
The objective of this phase I study was to determine the zzso tolerated dose zzso of the combination of weekly zzso and zzso in patients with advanced solid zzso 

Patients with advanced or zzso solid tumors were treated with intravenous weekly zzso with daily oral zzso The following dose levels zzso were zzso zzso zzso zzso bid, zzso zzso and zzso zzso was administered weekly for 6 weeks followed by 2 weeks off, and zzso was taken twice zzso Each cycle was 8 zzso 

zzso patients were enrolled in the zzso All of them had received prior systemic zzso Most patients had either melanoma or zzso of the upper gastrointestinal zzso A total of 31 cycles of therapy were zzso zzso were grade 3 zzso anorexia and fatigue and grade 3 zzso toxicity at dose level 4 zzso zzso was zzso zzso and gastrointestinal toxicity zzso zzso zzso abdominal pain and zzso represented the most common zzso However, grade 3 and grade 4 zzso were zzso There were no treatment related zzso No objective responses were observed and five patients achieved stable zzso 

The recommended dose for phase II studies is weekly zzso 35 zzso for 6 weeks followed by 2 weeks off in combination with oral zzso 250 zzso zzso zzso This combination is feasible and zzso at these zzso 

